Tech Company Financing Transactions
XenoPort Funding Round
On 2/4/2004, XenoPort landed $37 million in funding from GGV Capital, Arch Venture Partners and Frazier Healthcare Partners.
Transaction Overview
Company Name
Announced On
2/4/2004
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Undisclosed
Investors
GGV Capital (Lead Investor) (Joel Kellman)
Proceeds Purpose
This successful financing supports our confidence in the medical and commercial opportunities for XenoPorts product candidates, particularly XP13512, XenoPorts Transported Prodrug" of gabapentin
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3410 Central Expressway
Santa Clara, CA 95051
USA
Santa Clara, CA 95051
USA
Phone
Website
Email Address
Overview
XenoPort, Inc., based in Santa Clara, California, is a biopharmaceutical company focused on harnessing the bodys intrinsic cellular transport systems to improve the oral absorption, distribution and pharmacokinetics of drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ronald Barrett
Chief Financial Officer
William Harris
Chief Operating Officer
Vincent Angotti
VP - Regulatory Affairs
Gregory Bates
Browse more venture capital transactions:
Prev: 2/4/2004: Cornice venture capital transaction
Next: 2/6/2004: Vonage Holdings venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs